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Abstract
ADHD is the one of the most prevalent childhood disorders and has been
associated with impairments persisting into adulthood. Specifically, childhood
ADHD is an independent clinical risk factor for the development of later
substance use disorders (SUD). Moreover, adults who meet diagnostic criteria
for ADHD have shown high rates of comorbid SUDs. Few studies, however,
have reported on the relationship between ADHD subtypes and SUD in adult
samples. The purpose of this study was to characterize a clinical sample of
adults with ADHD and to identify possible associations between ADHD
subtypes, lifetime substance use, and if ADHD subtypes may be preferentially
associated with specific substances of abuse. We recruited 413 adult ADHD
patients, performed an evaluation of their ADHD and conducted an interview on
their use of psychotropic substances. Complete data was obtained for 349
patients. Lifetime substance abuse or dependence was 26% and occasional
use was 57% in this sample. The inattentive subtype was significantly less
likely to abuse or be dependent on cocaine than the combined subtype. Our
findings underscore the high rate of comorbidity between substance use and
ADHD in adults. The more frequent abuse/dependence of cocaine by adult
patients with hyperactive-impulsive symptoms should be kept in mind when
treating this patient group.
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Introduction
Attention-deficit/hyperactivity disorder (ADHD) is a complex 
neuropsychiatric syndrome that is common not only in childhood 
and adolescence, but in adulthood1–4. It is characterized by symp-
toms of inattention (distractibility), hyperactivity, and impulsiv-
ity, which all contribute to significant psychosocial impairment in 
affected individuals of all age groups5–7. In order to make a diag-
nosis of ADHD, the two diagnostic manuals, the American Psy-
chiatric Association’s (APA) Diagnostic and Statistical Manual 
of Mental Disorders Third Edition Revision (DSM-III-R) and the 
World Health Organisation’s (WHO) International Statistical Clas-
sification of Diseases and Related Health Conditions (ICD-10), 
require the presence of both inattentive and hyperactive-impulsive 
symptoms8,9.
In 1994, the introduction of the DSM Fourth Edition (IV)10 marked 
a diversion from this route by allowing for a diagnosis of ADHD 
when either hyperactive-impulsive or inattentive behaviors were 
present, and thereby defined three subtypes of ADHD: a) a predom-
inantly inattentive type, b) a predominantly hyperactive-impulsive 
type, and c) a combined type11. The following years saw a signifi-
cant amount of research in which the importance of these subtypes 
in a clinical and epidemiological context was debated. For exam-
ple, the clinical response to pharmacologic treatment by subtype or 
symptom clusters was investigated12–14, as were subtype differences 
in psychosocial functioning15,16, and the rate of comorbidity17 in dif-
ferent age groups.
In both pediatric and adult populations, ADHD is significantly 
comorbid with a wide range of other DSM-IV disorders, irrespec-
tive of subtype. The most prevalent of these are mood, anxiety, 
impulse control, and substance use disorders (SUD)18–20. Data that 
stem primarily from clinical and population-based studies suggest 
that up to 89% of all adults with ADHD suffer from a psychiat-
ric comorbidity during their lifetime16, and that the comorbidity 
of SUD in adolescents and adults with ADHD might range from 
16%–79%16,21–23. The heterogeneity of these data is also reflected in 
research focused on the association between specific ADHD sub-
types and SUDs. While some authors find no evidence of such an 
association, others have concluded that the hyperactive-impulsive 
subgroup is more likely to suffer from a comorbid SUD than is the 
inattentive subgroup15,22,24.
To our knowledge, few studies have reported on the relationship 
between ADHD subtypes and SUD in adult samples. Furthermore, 
the limited data available stems primarily from America, while the 
few European studies focused on several comorbid factors, not 
solely on SUD16,25. The purpose of this study was therefore to char-
acterize a clinical sample of adults with ADHD and to identify pos-
sible associations between ADHD subtypes, lifetime substance use, 
and preferences for specific substances.
Methods
Sample
Out of all consecutive referrals to the ADHD consultation service 
of the Zurich University Psychiatric Hospital26 between 2002 and 
2011, we included adults with a confirmed diagnosis of ADHD and 
with available information on substance use (N=413). There were 
no other inclusion or exclusion criteria.
Assessment of ADHD symptomatology
The diagnosis of ADHD was based on the Utah criteria for diagnos-
tic assessment with the Wender Reimherr Interview (WRI)27, and 
translated into German and validated for the German language by 
Rösler et al. and Retz-Junginger et al.28–30. According to DSM-IV 
Text Revision (TR)31 specifications, three ADHD subtypes were 
identified: a predominantly inattentive subtype, a predominantly 
hyperactive-impulsive subtype, and a combined subtype. Subtypes 
were derived from the Attention Deficit-/Hyperactivity Self-Report 
Scale (ADHS-SB) questionnaire (see Supplementary material) by 
first summing the respective items (items 1–9 for “inattentive”, 
items 10–18 for “hyperactive-impulsive”). Then, a cut-off value 
of 6 had to be exceeded in order for the respective subtype to be 
assigned. Subjects exceeding the threshold for both the inattentive 
and hyperactive-impulsive type were assigned to the combined sub-
type. As reported elsewhere32, patients also received a number of 
questionnaires, including German versions of the Symptom Check 
List 90-Revised (SCL-90-R)33, the Wender Utah Rating Scale 
(WURS-k)28, and the ADHS-SB34. If patients did not answer all 
questions on the questionnaire items, they were approached again 
and asked to supply the missing information. When patients had 
difficulty answering a question, their therapist helped to clarify it 
and enable them to provide an answer. In addition, third-party infor-
mation was sought from family members, spouses, school reports, 
and childhood medical reports to support the diagnostic procedure.
Assessment of substance use
Assessment of substance use was based on ICD-10 criteria (F10-
F19)9. Subjects reported on the lifetime use of alcohol, opioids, 
cannabinoids, sedatives, cocaine, (non-cocaine) stimulants, hallu-
cinogens, and tobacco. Substance use was differentiated into abuse/
dependence and sub-threshold, i.e. non-dependent and non-abusive, 
but more-than-singular, use.
Statistical analysis
Fisher’s exact tests were used to compare frequency of substance 
abuse/dependence and comorbidity rates between ADHD subtypes, 
since small cell sizes were frequent. Kruskal-Wallis tests were used 
to compare questionnaire scores. Bonferroni correction was applied 
to all substance-related significance tests. A total of 26 tests were 
conducted, resulting in a Bonferroni-corrected significance thresh-
old of p ≤.002. P-values surviving this threshold are printed in bold-
face in the results section. The study has low power: assuming a 
power of 80%, the minimal detectable difference in substance use 
frequency among subtypes is between 25–36%, while the power 
to detect a difference of 10% ranges from 28–48%. Analyses were 
carried out in Stata 11.2 and Stata 13.135.
Ethical framework
Authorization by the local ethics committee (Cantonal Ethics 
Committee Zurich; Kantonale Ethik Kommission Zürich (KEK)) 
was obtained before the study was conducted (04/2005). All par-
ticipants received a written description of the study procedure and 
signed a consent form.
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Results
Dataset 1. Contains all the variables necessary to reproduce the 
results of Adult attention-deficit/hyperactivity disorder
http://dx.doi.org/10.5281/zenodo.19623
Associations between subtype and lifetime substance use – a 
clinical study, Liebrenz et al.
A total of 64 subjects had no questionnaire data whatsoever and 
were dropped from further analysis. These “drop-outs” were com-
pared with the remaining 349 subjects and found not to differ in age 
and gender distribution. Drop-outs more often had affective disor-
ders (24.9% vs. 12.7%, p=.05). They tended to have less overall 
substance abuse or dependence (14.1% vs. 27.8%, p=.02). Total 
substance use excluding abuse and dependence was clearly lower 
in drop-outs (23.4% vs. 63.6%, p=.000).
The average age of the included sample was 38.7 years (SD = 11.28), 
with a gender distribution that was 56% male and 44% female. 
Other than substance use, the most common comorbidities included 
affective disorders (25%); neurotic, stress-related and somatoform 
disorders (15%); and personality disorders (6%).
In the sample with questionnaire data (N=332–345, depending 
on questionnaire participants reached average test scores of 35.4 
(SD=14.51) on WURS-k, 28.5 (SD=9.77) on ADHS-SB and 17.6 
(SD=7.87) on the newly developed SCL-ADHD scale18. A total of 
233 subjects were identified as belonging to the combined subtype 
of ADHD (test scores: ADHS-SB 32.9 [SD=7.69], WURS-k 37.5 
[SD=13.91], SCL-ADHD 19.4 [SD=7.62]), 70 belonged to the pre-
dominantly inattentive type (test scores: ADHS-SB 20.7 [SD=5.57], 
WURS-k 30.1 [SD=13.59], SCL-ADHD 14.2 [SD=6.52]), and 24 
belonged to the predominantly hyperactive-impulsive type (test 
scores: ADHS-SB 23.9 [SD=6.68], WURS-k 40.8 [SD=16.16], 
SCL-ADHD 16.4 [SD=7.28]). WURS-k (p<.04) and ADHS-SB 
(p<.0001) scores were different between inattentive and hyperac-
tive-impulsive subtypes, while all scores were different at p<.004 
for the comparison of inattentive vs. combined subtype.
According to ICD-10 F1x, 26% of all participants at the time of 
the study, regardless of subtype, fulfilled the criteria for abuse of 
or dependence on psychotropic substances other than nicotine. The 
most frequently misused substances consisted of alcohol (8.9%), 
opioids (6.0%), cannabinoids (8.3%), and cocaine (8.0%). Nicotine 
abuse/dependence was found in 20.3% of participants.
Subtype-specific analyses revealed that 36.9% of the combined 
subgroup, 44.3% of the predominantly inattentive subgroup, and 
41.7% of the hyperactive-impulsive subgroup currently suffered 
from a comorbid psychiatric disorder. Additionally, 31.3% of the 
combined-type individuals, 15.7% of the predominantly inattentive 
subjects and 41.7% of hyperactive-impulsive patients were diag-
nosed with abuse or dependence on a psychotropic substance other 
than nicotine. Table 1 summarizes the results.
Table 1. Lifetime substance use by ADHD subtype (p-values surviving Bonferroni threshold [p ≤ .002] 
in boldface).
Inattentive 
type
Hyperactive- 
impulsive 
typea
Combined 
type
pb 
inatt-hyp
pb 
inatt-
combined
N 70 24 233
% % %
Nicotine abuse/dependence 12.9 12.5 24.9 1.0 .03
Opiates abuse/dependence 1.4 12.5 7.3 .05 .08
Stimulants abuse/dependence 7.1 4.2 9.4 1.0 .64
Alcohol abuse/dependence 1.4 8.3 11.2 .16 .01
Cannabis abuse/dependence 5.7 16.7 8.6 .20 .61
Cocaine abuse/dependence 0 12.5 10.3 .02 .002
Substances total (w/o tobacco)  
abuse/dependence
15.7 41.7 31.3 .02 .01
Substances total (w/o tobacco) use 57.1 62.5 66.5 .81 .16
bFischer’s exact test
inatt-hyp = inattentive vs. hyperactive-impulsive subtype, inatt-combined = inattentive vs combined subtype
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Discussion
The present study investigated associations between the combined 
and predominantly inattentive subtypes of adults with ADHD and 
lifetime substance use, within a clinical sample. The most clinically 
significant result is the finding that the inattentive subtype showed a 
statistically significantly smaller rate of cocaine abuse/dependence 
compared to the combined subtype.
These results are in line with earlier work by Sobanski et al., who 
had characterized a sample of 118 adults with ADHD and found that 
the combined type suffered significantly more from lifetime SUDs 
(48.4%) than did patients with a predominantly inattentive type 
(23.3%)16. On the other hand, our findings contrast with results pub-
lished by Clure et al., who reported on 43 patients with adult ADHD 
but found no differences in ADHD subtypes when divided by sub-
stance of choice (cocaine, alcohol, and multiple substances)36.
The most frequently consumed substance among all study par-
ticipants was nicotine. This finding is in accord with results from 
prior studies37–39. With regard to subtype-specific differences, some 
authors have reported that, at least in young adolescents, the inat-
tentive subtype of ADHD is more likely to correlate with higher 
levels of nicotine use than does the combined subtype40. It was 
suggested that nicotine might primarily improve attention but have 
less influence on hyperactive-impulsive behavior, which might 
explain this finding41,42. Other researchers, however, suggest that 
hyperactive-impulsive symptoms present a greater risk for frequent 
nicotine use than do inattentive symptoms at a later age, and argue 
that the relationship between ADHD symptoms and nicotine use 
might change between adolescence and adulthood43.
Our hypothesis that findings would show continuing preferences 
for the use of specific substances in adulthood according to subtype 
(beyond cocaine), remains open due to lack of statistical signifi-
cance. Like earlier reports of (non-cocaine) stimulants being used 
as self-medication by patients with ADHD, we had also expected 
to find a higher rate of non-prescribed lifetime stimulant abuse/
dependence in the hyperactive-impulsive type, but not in the inat-
tentive one44,45. In this sample, however, we found no evidence for 
this assumption, but lack of statistical power precludes interpreting 
this as evidence of no difference. We suspect that adults with both 
hyperactive-impulsive and inattentive symptoms might initially 
prefer cocaine to stimulants for self-medication, but there is no 
direct evidence for this assessment46–48.
The possibility of using cocaine as an attempt to self-medicate for 
ADHD symptoms was originally proposed in the early ’90s49,50. More 
recently, Saules et al. compared the symptom profile among adult 
ADHD smokers with and without cocaine dependence, and found that 
when they corrected for the use of nicotine, adults who used cocaine 
exhibited a more severe adult ADHD symptom profile, as accounted 
for by the presence of elevated hyperactive-impulsive but not inatten-
tive symptoms. He therefore suggested that cocaine use in smokers 
with ADHD might be driven by excesses in hyperactivity50. Despite 
differences in sampling, our results are in accord with this finding.
The main limitation of this study is low power. This means, in 
particular, that non significant findings cannot be interpreted as evi-
dence of no difference. A further limitation is that our sample was 
recruited entirely within a university setting, which might contrib-
ute to a selection bias. As a result, this clinical sample might have 
different characteristics than patients would exhibit who are in treat-
ment with a physician in private practice. Nevertheless, the ADHD 
consultation service of the Psychiatric University Hospital Zurich is 
the largest institution of its kind in Switzerland and attracts patients 
from diverse psychosocial backgrounds.
In conclusion, our findings underscore the high rate of comor-
bidity between substance use and ADHD in adults. The more 
frequent abuse/dependence of cocaine by adult patients with 
hyperactive-impulsive symptoms should be kept in mind when treat-
ing this patient group. Although a limited number of evidence-based 
treatment strategies currently exist for the concurrent treatment of 
ADHD and SUD, some studies suggest that stimulant medica-
tion remains an efficacious pharmacological treatment option that 
improves symptoms of ADHD without increasing the likelihood of 
relapse into SUD22,51.
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